- Home
- ILMN vs EQR Comparison
ILMN vs EQR Comparison
Compare ILMN & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- EQR
- Stock Information
- Founded
- ILMN 1998
- EQR 1993
- Country
- ILMN United States
- EQR United States
- Employees
- ILMN N/A
- EQR N/A
- Industry
- ILMN Medical Specialities
- EQR Real Estate Investment Trusts
- Sector
- ILMN Health Care
- EQR Real Estate
- Exchange
- ILMN Nasdaq
- EQR Nasdaq
- Market Cap
- ILMN 13.1B
- EQR 26.7B
- IPO Year
- ILMN 2000
- EQR 1993
- Fundamental
- Price
- ILMN $99.25
- EQR $66.74
- Analyst Decision
- ILMN Buy
- EQR Buy
- Analyst Count
- ILMN 17
- EQR 15
- Target Price
- ILMN $124.35
- EQR $78.93
- AVG Volume (30 Days)
- ILMN 2.4M
- EQR 2.1M
- Earning Date
- ILMN 07-31-2025
- EQR 08-04-2025
- Dividend Yield
- ILMN N/A
- EQR 4.15%
- EPS Growth
- ILMN N/A
- EQR 8.50
- EPS
- ILMN N/A
- EQR 2.62
- Revenue
- ILMN $4,337,000,000.00
- EQR $3,010,100,000.00
- Revenue This Year
- ILMN N/A
- EQR $5.13
- Revenue Next Year
- ILMN $3.15
- EQR $4.31
- P/E Ratio
- ILMN N/A
- EQR $25.52
- Revenue Growth
- ILMN N/A
- EQR 3.81
- 52 Week Low
- ILMN $68.70
- EQR $59.41
- 52 Week High
- ILMN $156.66
- EQR $78.84
- Technical
- Relative Strength Index (RSI)
- ILMN 65.51
- EQR 42.16
- Support Level
- ILMN $95.09
- EQR $66.04
- Resistance Level
- ILMN $101.28
- EQR $67.54
- Average True Range (ATR)
- ILMN 3.28
- EQR 1.29
- MACD
- ILMN 0.10
- EQR -0.03
- Stochastic Oscillator
- ILMN 78.82
- EQR 33.12
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.